COLUMBANO, AMEDEO
 Distribuzione geografica
Continente #
EU - Europa 250.788
NA - Nord America 12.145
AS - Asia 4.917
SA - Sud America 683
AF - Africa 115
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 4
Totale 268.674
Nazione #
IT - Italia 242.874
US - Stati Uniti d'America 11.969
NL - Olanda 4.810
SG - Singapore 1.900
CN - Cina 1.721
UA - Ucraina 886
SE - Svezia 643
BR - Brasile 512
DE - Germania 462
VN - Vietnam 434
FI - Finlandia 374
GB - Regno Unito 282
FR - Francia 244
HK - Hong Kong 160
IN - India 118
CA - Canada 114
KR - Corea 96
TR - Turchia 87
BD - Bangladesh 70
AR - Argentina 59
IQ - Iraq 47
JP - Giappone 47
RU - Federazione Russa 40
ID - Indonesia 37
MX - Messico 33
ZA - Sudafrica 32
PL - Polonia 28
PK - Pakistan 27
ES - Italia 26
BE - Belgio 24
CO - Colombia 24
VE - Venezuela 24
MA - Marocco 23
IR - Iran 22
AU - Australia 21
SA - Arabia Saudita 21
PH - Filippine 20
EC - Ecuador 19
AT - Austria 18
CL - Cile 14
JO - Giordania 14
UZ - Uzbekistan 13
EG - Egitto 12
KE - Kenya 12
LT - Lituania 12
PY - Paraguay 12
IE - Irlanda 10
MY - Malesia 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
AZ - Azerbaigian 9
DZ - Algeria 9
IL - Israele 9
PE - Perù 9
JM - Giamaica 7
BG - Bulgaria 6
RO - Romania 6
CZ - Repubblica Ceca 5
ET - Etiopia 5
HN - Honduras 5
KZ - Kazakistan 5
MT - Malta 5
PS - Palestinian Territory 5
TH - Thailandia 5
UY - Uruguay 5
AL - Albania 4
CH - Svizzera 4
EU - Europa 4
HU - Ungheria 4
PA - Panama 4
BO - Bolivia 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
GE - Georgia 3
KH - Cambogia 3
NP - Nepal 3
OM - Oman 3
PT - Portogallo 3
TW - Taiwan 3
BB - Barbados 2
BH - Bahrain 2
CR - Costa Rica 2
CY - Cipro 2
DK - Danimarca 2
EE - Estonia 2
GR - Grecia 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LV - Lettonia 2
MU - Mauritius 2
NI - Nicaragua 2
NO - Norvegia 2
RS - Serbia 2
SR - Suriname 2
TT - Trinidad e Tobago 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
CD - Congo 1
Totale 268.657
Città #
Cagliari 238.602
Amsterdam 4.788
Uta 3.758
Fairfield 1.293
Ashburn 1.063
Singapore 969
Woodbridge 854
Chandler 792
San Jose 708
Houston 614
Wilmington 530
Boardman 523
Ann Arbor 489
Seattle 488
Nyköping 471
Jacksonville 464
Cambridge 441
Dallas 370
Beijing 336
Dearborn 245
Los Angeles 238
Helsinki 211
Santa Clara 161
Nanjing 153
Lauterbourg 152
Hong Kong 140
Ho Chi Minh City 131
The Dalles 125
Boston 105
New York 102
Hanoi 95
Hefei 92
Seoul 90
Shanghai 88
Buffalo 87
San Diego 78
Guangzhou 77
Toronto 63
Kocaeli 58
Shenyang 58
Nanchang 57
São Paulo 56
Council Bluffs 54
Redwood City 53
Changsha 52
Hebei 51
Falls Church 49
San Mateo 48
Milan 46
Mountain View 45
London 43
Munich 40
Frankfurt am Main 38
Dong Ket 36
Jiaxing 36
Redondo Beach 36
Chicago 34
Tianjin 33
Tokyo 31
Jinan 28
Atlanta 27
Orem 26
Warsaw 26
Norwalk 25
Auburn Hills 24
Montreal 24
Brussels 23
Brooklyn 22
Leawood 22
Augusta 21
Orange 21
Phoenix 21
Rome 21
Baghdad 20
Nuremberg 20
Rio de Janeiro 20
Turku 20
Verona 20
Manchester 19
Stockholm 19
Chennai 18
Millbury 18
Zhengzhou 18
Da Nang 17
Denver 17
Johannesburg 17
Minneapolis 17
Biên Hòa 15
Pune 15
Ardabil 14
Casablanca 14
Pisa 13
Amman 12
Columbus 12
Haiphong 12
Hải Dương 12
Ningbo 12
Tashkent 12
Washington 12
Dhaka 11
Totale 261.697
Nome #
null 13.191
Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype 6.013
Expression of c-jun is not mandatory for mouse hepatocyte proliferation induced by two nuclear receptor ligands: TCPOBOP and T3 4.971
Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice 4.235
YAP activation is an early event and a potential therapeutic target in liver cancer development 4.043
Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats 3.958
Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats 3.875
TRbeta is the critical thyroid hormone receptor isoform in T3-induced proliferation of hepatocytes and pancreatic acinar cells 3.752
Alpha-lipoic acid promotes the growth of rat hepatic preneoplastic lesions in the choline deficient model 3.712
Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis 3.709
Increased ROS generation and p53 activation in alpha-lipoic acid-induced apoptosis of hepatoma cells 3.664
Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis 3.656
Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor 3.594
Emerging role of the pentose phosphate pathway in hepatocellular carcinoma 3.589
Clustered protocadherins methylation alterations in cancer 3.318
Induction of hepatocyte proliferation by retinoic acid 3.317
Sex difference in the proliferative response of mouse hepatocytes to treatment with the CAR ligand TCPOBOP 3.227
The peroxisome proliferator BR931 kills FaO cells by p53-dependent apotosis 3.183
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis 3.183
MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). 3.167
MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. 3.159
Potential utility of xenobiotic mitogens in the context of liver regeneration in the elderly and living-related transplantation 3.125
Cyclin D1 is an early target in hepatocyte proliferation induced by thyroid hormone (T3) 3.112
Induction of autophagy promotes the growth of early preneoplastic rat liver nodules 3.092
The thyromimetic KB2115 (Eprotirome) induces rat hepatocyte proliferation 2.973
The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival 2.909
Regulatory effects of senescence marker protein 30 on the proliferation of hepatocytes 2.800
Reply to: "YAP in tumorigenesis: Friend or foe?" 2.767
Progenitor-derived hepatocellular carcinoma model in the rat 2.746
A long term, non-tumorigenic rat hepatocyte cell line and its malignant counterpart, as tools to study hepatocarcinogenesis 2.734
High frequency of β-catenin mutations in mouse hepatocellular carcinomas induced by a nongenotoxic constitutive androstane receptor agonist 2.651
Timed regulation of P-element-induced wimpy testis-interacting RNA expression during rat liver regeneration 2.643
T3/TRs axis in hepatocellular carcinoma: new concepts for an old pair 2.636
Estimation of a significance threshold for epigenome-wide association studies 2.584
Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression 2.555
Cell proliferation and cell death in rat liver carcinogenesis by chemicals 2.533
Thyroid hormone induces cyclin D1 nuclear translocation and DNA synthesis in adult rat cardiomyocytes 2.510
Effect of choline administration on the toxicity of N-nitrosodimethylamine in female rats 2.495
The thyroid hormone receptor-beta agonist GC-1 induces cell proliferation in rat liver and pancreas 2.474
Induction of pancreatic acinar cell proliferation by thyroid hormone 2.474
Genetic inactivation of Nrf2 prevents clonal expansion of initiated cells in a nutritional model of rat hepatocarcinogenesis 2.437
null 2.399
Ciprofibrate and triiodothyronine do not suppress in vivo induction of placental glutathione S-transferase expression in rat hepatocytes 2.387
Early increase in cyclin-D1 expression and accelerated entry of mouse hepatocytes into S phase after administration of the mitogen 1,4-bis[2-(3,5-dichloropyridyloxy)] benzene 2.377
Reply to: Clinical correlation of miR-375 and alpha-fetoprotein in hepatocellular carcinoma: comparison in mice and humans 2.358
Thyroid hormones, thyromimetics and their metabolites in the treatment of liver disease 2.329
Gadd 45beta is induced through a CAR-dependent, TNF-independent pathway in murine liver hyperplasia 2.324
Gadd45β is an inducible coactivator of transcription that facilitates rapid liver growth in mice 2.225
Proteomic characterization of early changes induced by triiodothyronine in rat liver 2.173
Gender-specific interplay of signaling through β-catenin and CAR in the regulation of xenobiotic-induced hepatocyte proliferation 2.125
Cell proliferation induced by 3,3',5 triiodo L thyronine is associated with a reduction in the number of preneoplastic hepatic lesions 2.114
Triiodothyronine induces hepatocyte proliferation by protein kinase A-dependent-b-catenin activation in rodents. 2.111
DEXAMETHASONE INHIBITS INDUCTION OF LIVER-TUMOR NECROSIS FACTOR-ALPHA MESSENGER-RNA AND LIVER GROWTH INDUCED BY LEAD NITRATE AND ETHYLENE DIBROMIDE 2.075
Thyroid hormone receptor-β agonist induces β-catenin-dependent hepatocyte proliferation in mice: Implications in hepatic regeneration 1.962
AGING DOES NOT REDUCE THE HEPATOCYTE PROLIFERATIVE RESPONSE OF MICE TO THE PRIMARY MITOGEN TCPOBOP 1.923
METODO PER RILEVARE E/O PER LA PROGNOSI DI NEOPLASIE DEL COLON-RETTO 1.856
Different effects of regenerative and direct mitogenic stimuli on the growth of initiated cells in the resistant hepatocyte model 1.851
A large set of miRNAs is dysregulated from the earliest steps of human hepatocellular carcinoma development 1.844
Compensatory regeneration, mitogen-induced liver growth, and multistage chemical carcinogenesis 1.802
miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling 1.788
Different effects of the liver mitogens triiodo-thyronine and ciprofibrate on the development of rat hepatocellular carcinoma 1.784
Dexametasone inhibits induction of liver Tumor Necrosis Factor-a mRNA and liver growth induced by lead nitrate and ethylene dibromide 1.768
Cell proliferation induced by triiodothyronine in rat liver is associated with nodule regression and reduction of hepatocellular carcinomas 1.763
The dual roles of NRF2 in cancer 1.721
Thyroid Hormone Receptor-β Agonist GC-1 Inhibits Met-β-Catenin-Driven Hepatocellular Cancer 1.718
Loss of cyclin D1 does not inhibit the proliferative response of mouse liver to mitogenic stimuli 1.699
Increased expression of c.fos, c-jun and LRF-1 is not required for in vivo priming of hepatocytes by the mitogen TCPOBOP 1.691
Animal models: A useful tool to unveil metabolic changes in hepatocellular carcinoma 1.667
Peroxisome proliferator-activated receptor-alpha(-/-) mice show enhanced hepatocyte proliferation in response to the hepatomitogen 1,4-bis[2-(3,5-dichloropyridyloxy)] benzene, a ligand of constitutive androstane receptor 1.648
Differential effects of choline administration on liver microsomes of female and male rats 1.644
Differences in the steady-state levels of c-fos, c-jun and c-myc messanger RNA during mitogen-induced liver growth and compensatory regeneration 1.638
Constitutive androstane receptor (Car)-driven regeneration protects liver from failure following tissue loss 1.619
Studies on the kinetics of expression of cell cycle dependent proto-oncogenes during mitogen-induced liver cell proliferation 1.580
MicroRNA: New Tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? 1.561
Liver cell proliferation induced by nafenopin and cyproterone acetate is not associated with increases in activation of trascription factors NF-kB and AP-1 or expression of tumor necrosis factor-alfa 1.496
Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis 1.458
Met as a therapeutic target in HCC: Facts and hopes 1.447
An electron microscopic study of apoptosis induced by cycloheximide in rat liver 1.418
A common set of immediate-early response genes in liver regeneration and hyperplasia 1.392
Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming 1.216
Early ultrastructural changes during thioacetamide-induced apoptosis in rat liver 1.180
Mitogenesis by ligands of nuclear receptors: an attractive model for the study of the molecular mechanisms implicated in liver growth 1.171
Genome-wide single nucleotide polymorphysm analysis of lung cancer risk detects the KLF6 gen 1.098
The TRbeta-selective agonist, GC-1, stimulates mitochondrial oxidative processes to a lesser extent than triiodothyronine 1.049
Potential role of two novel agonists of thyroid hormone receptor-β on liver regeneration 964
Tg68, a novel thyroid hormone receptor‐β agonist for the treatment of NAFLD 964
Hexose monophosphate shunt and cholesterogenesis in lead-induced kidney hyperplasia 958
null 951
Nrf2 Mutation/Activation Is Dispensable for the Development of Chemically Induced Mouse HCC 895
HMP-shunt and cholesterol metabolism in experimental models involving normal and preneoplastic liver growth. 889
Stimulation of DNA synthesis after a single administration of cadmium nitrate. 880
Roles of growth factors and of tumor necrosis factor-alpha on liver cell proliferation induced in rats by lead nitrate 870
Cell proliferation in rat kidney induced by 1,2-dibromoethane 867
Induction of 2 different modes of cell-death, apoptosis and necrosis, in rat-liver after a single dose of thioacetamide 866
Occurence of cell death (Apoptosis) during the involution of liver hyperplasia 865
T3 and the thyroid hormone beta-receptor agonist GC-1 differentially affect metabolic capacity and oxidative damage in rat tissues 862
Liver hyperplasia is not necessarily associated with increased expression of c-fos and c-myc mRNA 861
Induction of cellular DNA synthesis in the pancreas and kidneys of rats by peroxisome proliferators, 9-cis retinoic acid, and 3,3',5-triiodo-L-thyronine 851
Further evidence that mitogen-induced cell proliferation does not support the formation of enzyme-altered islands in rat liver by carcinogens 845
Cell deletion by apoptosis during regression of renal hyperplasia. 841
Totale 233.444
Categoria #
all - tutte 335.544
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 335.544


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.487 0 0 0 0 0 0 0 0 0 0 2.957 1.530
2021/202213.864 1.847 1.210 687 919 1.129 1.048 748 561 1.468 1.236 1.423 1.588
2022/202319.224 1.491 2.529 2.506 1.704 1.674 1.833 994 1.502 1.175 1.324 1.568 924
2023/202419.982 1.380 925 1.896 1.415 1.808 2.537 2.702 1.442 910 1.379 1.788 1.800
2024/202530.988 7.855 8.128 3.496 3.015 1.668 2.020 2.223 180 336 1.351 299 417
2025/202612.887 598 577 937 898 816 586 2.240 519 4.410 1.281 25 0
Totale 269.041